| |
Propensity score weighting
|
|---|
|
With CKD
|
Without CKD
|
|---|
|
ACEi (n = 932)
|
ARB (n = 2135)
|
Standardized mean difference
|
ACEi (n = 5966)
|
ARB (n = 10,623)
|
Standardized mean difference
|
|---|
|
Duration from DM to index date (years)
|
3.50 ± 3.33
|
3.52 ± 2.09
|
−0.0049
|
3.00 ± 3.11
|
3.01 ± 2.29
|
−0.0035
|
|
Age (years) (mean ± SD)
|
65.5 ± 13.3
|
65.2 ± 8.8
|
0.0276
|
60.8 ± 12.9
|
60.6 ± 9.8
|
0.0175
|
|
Age group (years)
| | |
0.0123
| | |
0.0049
|
|
20–49 (%)
|
14.70
|
15.06
| |
21.81
|
21.92
| |
|
50–64 (%)
|
32.08
|
32.25
| |
40.56
|
40.69
| |
|
65+ (%)
|
53.22
|
52.69
| |
37.63
|
37.39
| |
|
Male sex
|
59.12 %
|
59.21 %
|
−0.0019
|
59.52 %
|
59.62 %
|
−0.0019
|
|
Congestive heart failure
|
8.05 %
|
8.15 %
|
−0.0039
|
3.96 %
|
3.94 %
|
0.0006
|
|
Stroke
|
16.20 %
|
16.15 %
|
0.0014
|
12.19 %
|
12.16 %
|
0.0007
|
|
Malignant dysrhythmia
|
0.21 %
|
0.21 %
|
0.0014
|
0.49 %
|
0.48 %
|
0.0011
|
|
Cardiogenic shock
|
0.64 %
|
0.73 %
|
−0.0102
|
0.27 %
|
0.27 %
|
−0.0011
|
|
MI/PCI
|
5.15 %
|
5.08 %
|
0.0030
|
4.98 %
|
4.96 %
|
0.0008
|
|
CABG
|
0.11 %
|
0.11 %
|
−0.0010
|
0.52 %
|
0.51 %
|
0.0008
|
|
Thrombolysis therapy
|
0.00 %
|
0.00 %
|
−0.0002
|
0.28 %
|
0.28 %
|
0.0012
|
|
Hyperlipidemia
|
59.44 %
|
59.86 %
|
−0.0085
|
53.77 %
|
53.77 %
|
−0.0017
|
|
Incidence of ESRDa
|
1.39
|
2.34
| |
0.30
|
0.37
| |
|
(95 % CI)
|
(1.00−1.78)
|
(1.80−2.89)
| |
(0.23−0.37)
|
(0.29−0.46)
| |
-
DM diabetes mellitus, ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, CKD chronic kidney diseases, MI myocardial infarction, PCI percutaneous coronary intevention, CABG coronary artery bypass graft surgery
-
aIncidence per 100 person-years
